HDAC-IN-35 (Compound 14) 是一个有效的、选择性的HDAC和VEGFR-2抑制剂，对HDAC6和VEGFR-2的IC50值分别为0.166和13.2 μM。
| 生物活性 | HDAC-IN-35 (Compound 14) is a potent, selectiveHDACandVEGFR-2inhibitor, withIC50values of 0.166 and 13.2 μM forHDAC6andVEGFR-2, respectively[1]. |
| IC50& Target | HDAC6 0.166 μM (IC50) | HDAC8 1.99 μM (IC50) | HDAC1 7.23 μM (IC50) | VEGFR2 13.2 μM (IC50) |
|
体外研究
(In Vitro) | HDAC-IN-35 (Compound 14) (0-10 μM, 48 h) shows anticancer effects in different cancer cells[1].
HDAC-IN-35 (0-10 μM, 48 h) exhibits potent anti-angiogenic activity with a GI>50(50% growth inhibition) value of 1.0 μM on human endothelial progenitor cells (EPCs) through a VEGFR-2-dependent pathway, without obvious systemic toxicity[1].
HDAC-IN-35 exhibits moderate VEGFR-2 inhibitory activities and displays the anticancer effects by inhibiting the enzymatic activity of HDAC[1].
HDAC-IN-35 (0-10 μM, 24 h) concentration-dependently impedes the capillary-like tube formation in human EPCs[1].
Cell Viability Assay[1] | Cell Line: | A549, PC-3, and SK-Hep-1 | | Concentration: | 0-10 μM | | Incubation Time: | 48 h | | Result: | Showed anticancer effects with IC50values of 3.4, 1.9 and 3.2 μM against A549, PC-3, and SK-Hep-1 cells. |
Western Blot Analysis[1] | Cell Line: | A549, PC-3, and SK-Hep-1, and human EPCs | | Concentration: | 0, 5, and 10 μM | | Incubation Time: | 24 h | | Result: | Increased the amount of acetylated α-tubulin and histone H3 in a concentration-dependent manner in cancer cells. Induced mild inhibition of the phosphorylation of VEGFR-2 in human EPCs. |
|
| 分子量 | |
| Formula | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com